Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade

NCT04340882 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Non-Small Lung Cell Cancer
Recurrent Non-Small Lung Cell Cancer
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

DRUG: Docetaxel
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Ramucirumab

Sponsor

Emory University

Collaborators

[object Object]
[object Object]